Market revenue in 2023 | USD 23.2 million |
Market revenue in 2030 | USD 161.3 million |
Growth rate | 31.9% (CAGR from 2023 to 2030) |
Largest segment | Drug optimization & repurposing |
Fastest growing segment | Drug Optimization & Repurposing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Drug Optimization & Repurposing, Preclinical Testing |
Key market players worldwide | International Business Machines Corp, Exscientia PLC ADR, Alphabet Inc Class A, Benevolent AI, Recursion Pharmaceuticals Inc Class A, Aitia, BioSymetrics, Euretos, Berg, Atomwise, Insitro |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to artificial intelligence in drug discovery market will help companies and investors design strategic landscapes.
Drug optimization & repurposing was the largest segment with a revenue share of 53.88% in 2023. Horizon Databook has segmented the South Korea artificial intelligence in drug discovery market based on drug optimization & repurposing, preclinical testing covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing implementation of AI in drug discovery owing to various benefits, including development of state-of-the-art algorithms by utilizing the latest advancements in biology & computing, reducing the potential for false positives, and reducing the overall cost of drug discovery & development.
Is expected to boost South Korea’s market. Increasing investments by various public and private organizations have also increased the adoption of AI in drug discovery. The funding round was led by Mirae Asset Capital & Mirae Asset Venture Investment.
Aimed at scaling AI technology platforms and advancing its drug discovery pipeline toward license-out. In June 2019, The Korean government announced spending 25.8 billion KRW for supporting the discovery & development of innovative medicines in the next three years by using AI.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea artificial intelligence in drug discovery market , including forecasts for subscribers. This country databook contains high-level insights into South Korea artificial intelligence in drug discovery market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account